AMP Rule Withdrawal Previews Potential Issues When CMS Revisits Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
Commenters target a variety of issues including federal upper limit requirements and impact on 340B pricing.
You may also be interested in...
Pharmacy Groups Say Draft Medicaid FULs Could Lead To Rx Access Issues
Associations representing retail pharmacies say faults in CMS’ draft average manufacturer price-based federal upper limits for multiple source drugs could result in reduced access to drugs by the Medicaid population.
Pharmacy Groups Say Draft Medicaid FULs Could Lead To Rx Access Issues
Associations representing retail pharmacies say faults in CMS’ draft average manufacturer price-based federal upper limits for multiple source drugs could result in reduced access to drugs by the Medicaid population.
In Absence Of AMP Rules From CMS, Manufacturers Make Their Own
Drug manufacturers have been submitting average manufacturer price data to CMS using a new definition of AMP established by the Affordable Care Act. But they have been on their own when it comes to interpreting how to apply ACA to their calculation of AMP.